Sareum Holdings PLC TYK2/JAK1 selected for certain cancers (9213B)
September 26 2018 - 1:00AM
UK Regulatory
TIDMSAR
RNS Number : 9213B
Sareum Holdings PLC
26 September 2018
(AIM: SAR) 26 September 2018
This announcement contains inside information for the purposes
of Article 7 of Regulation 596/2014
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Potent, selective small molecule inhibitor of TYK2/JAK1 selected
for further development as potential treatment for certain types of
leukaemia, lymphoma and solid tumour
Sareum Holdings plc (AIM: SAR), the drug discovery and
development company, announces that it has made the formal
selection of a development candidate from its TYK2 inhibitor
programme to advance through preclinical development as a potential
new targeted therapy for certain cancers.
The candidate molecule, SDC-1802, demonstrated high selectivity
for TYK2 and JAK1 kinases (particularly over related JAK2 and
JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell
proliferation in cellular and disease models of T-cell acute
lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential
for once-daily oral dosing and a good early safety profile. In
addition, Sareum has generated encouraging evidence to suggest that
these molecules can function as cancer immunotherapy by modulating
the host's immune system to block tumour cell proliferation in
disease models of certain kidney, colon, skin and pancreatic
cancers.
Sareum intends to progress SDC-1802 into preclinical development
(and pending satisfactory progress) into human clinical trials
which could begin in 2020. The Company owns the commercialisation
rights for these candidates and other dual TYK2/JAK1 inhibitors
with profiles optimised for oncology indications.
Sareum announced on 10 September 2018 that it is also advancing
SDC-1801 as a distinct dual TYK2/JAK1 inhibitor for the potential
treatment of autoimmune diseases, including psoriasis, rheumatoid
arthritis, inflammatory bowel disease and lupus. SDC-1802 also has
the potential to act as a back-up molecule for these autoimmune
indications.
Dr Tim Mitchell, CEO of Sareum, commented: "We are very pleased
to have formally selected lead candidates from our TYK2 inhibitor
programme for both cancer and autoimmune diseases. The candidates
are distinct small molecules with attractive and highly competitive
profiles for development in their respective indications. Both
candidates have produced exciting results in preclinical disease
models and we believe present valuable opportunities for licensing
and/or further development. Our focus is now to advance both
candidates into clinical studies, which we anticipate beginning in
2020."
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7638 9571
Notes for editors:
About TYK2 and JAK1 kinases
TYK2 and JAK1 are members of the Janus Kinase (JAK) family of
protein kinase enzymes with roles in tumour cell proliferation in
certain cancers and pro-inflammatory responses in autoimmune
diseases. Members of the JAK family are the targets of several
marketed and clinical-stage drugs for cancer and autoimmune
diseases, although there are currently no marketed products
specifically targeting TYK2.
About Sareum Holdings plc
Sareum is a drug discovery and development company delivering
targeted small molecule therapeutics, focusing on cancer and
autoimmune disease. The Company generates value through licensing
its candidates to international pharmaceutical and biotechnology
companies at the preclinical or early clinical trials stage.
Sareum's leading clinical-stage programme, SRA737, a novel
Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed
Sierra Oncology, is in Phase 2 clinical trials targeting ovarian
and other advanced cancers. The key role of Chk1 in cancer cell
replication and DNA damage repair suggests that SRA737 may have
broad application as a targeted therapy in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
Sareum is also advancing internal programmes focused on distinct
dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors
through preclinical development as therapies for autoimmune
diseases and cancers. TYK2 and JAK1 have roles in pro-inflammatory
responses in autoimmune diseases (e.g. psoriasis, rheumatoid
arthritis, inflammatory bowel diseases and lupus) and tumour cell
proliferation in certain cancers (e.g. T-cell acute lymphoblastic
leukaemia and some solid tumours). The Company is targeting first
human clinical trials in each indication in 2020.
The Company also has an Aurora+FLT3 inhibitor targeting
haematological cancers, which is at the preclinical development
stage.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFMGZLVKDGRZM
(END) Dow Jones Newswires
September 26, 2018 02:00 ET (06:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024